IDF21-0018 Patient Reported Outcomes for Tirzepatide versus Semaglutide in Participants with T2D from the SURPASS-2 Trial

      Background: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, is in development for T2D treatment. The SURPASS-2 trial assessed efficacy and safety of once weekly tirzepatide (5mg, 10mg, 15mg) versus semaglutide (1mg) in people with T2D on background metformin.
      Aim: To assess SURPASS-2 patient-reported outcomes.
      Method: Participants completed three weight-related questionnaires at baseline and at 40 weeks: the Impact of Weight on Self-Perception (IW-SP), the Ability to Perform Physical Activities of Daily Living (APPADL), the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT). Additionally, the Diabetes Treatment Satisfaction Questionnaire (DTSQ; measuring treatment satisfaction and perceived frequency of hyper/hypoglycemia), and the EQ-5D-5L (a measure of health status) were completed.
      Discussion: Improvements in health-related quality of life patient-reported outcomes were observed in both tirzepatide- and semaglutide-treated participants with greater improvements observed in weight-related quality of life outcomes with tirzepatide higher doses compared to semaglutide.